Open an account

Dyadic International

DYAI · NASDAQ

$0.3851+$0.0042 (+1.10%)TodayMarket closed ·
Prev close $0.3809

DYAI analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 4 analysts

Average $5.61 (+1356.8% upside)

Low
$4.04
Now
$0.3851
High
$7.35

Upgrades and downgrades

The latest rating actions, newest first

DYAI analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Oct 23, 2025InitiatesBuy

The case for and against

Updated Dec 28, 2024

Bull case

Dyadic International Inc. has reported substantial revenue growth in its 3Q24 financial results, attributed to increased interest in its gene expression platform, C1, and the proprietary Dapibus technology, both of which have gained traction in licensing agreements. The company recognized $1 million in licensing revenue from a deal with PHB and an additional success fee of $425,000 from Inzymes ApS for developing non-animal dairy enzymes. This positive momentum reflects Dyadic's strategic positioning to capitalize on the rising demand for cost-effective production of biologic products, such as therapeutics and vaccines, enhancing its prospects for future growth.

Bear case

Dyadic International Inc. reported a net loss of $0.2 million in the third quarter of 2024, indicating ongoing financial struggles as the company continues to invest in its biotechnology platform. The company faces significant risks, including the possibility of unsuccessful clinical trials and the challenges associated with regulatory requirements for further studies, which could hinder its commercialization efforts. Additionally, there are concerns regarding the company’s ability to differentiate its products competitively, potential issues with intellectual property rights, and the risk of needing to secure additional funding under adverse market conditions.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.